TetraLogic Pharmaceuticals Corporation presented results from the Phase I randomized, placebo-controlled clinical study of SHAPE (formerly SHP-141) in Stage IA -IIA Cutaneous T Cell Lymphoma (CTCL) at the annual Society of Investigative Dermatology Meeting, which was held in Albuquerque, New Mexico.

SHAPE (Suberohydroxamic acid phenyl ester) is a histone deacetylase (HDAC) inhibitor being developed for topical use for the treatment of CTCL. According to the company, SHAPE is a novel therapeutic intentionally designed to maximize HDAC inhibition locally in the skin with limited systemic exposure. As a result, SHAPE has characteristics
that could allow it to be used topically over large body surface areas without systemic absorption. SHAPE demonstrated safety and clinical activity in a randomized, dose escalation placebo-controlled Phase I clinical trial in early CTCL subjects. A randomized Phase 2 clinical trial to evaluate SHAPE in early stage CTCL is expected to commence by the end of 2014. SHAPE's composition of matter patent in the U.S. extends until at least 2028; in addition, SHAPE has been granted U.S. orphan drug designation for CTCL. TetraLogic acquired worldwide development and commercialization rights to SHAPE for all indications.